Indeed, previous clinical studies have clearly shown that patients with any HF phenotype have an elevated risk of mortality and hospitalization beyond that estimated by levels of natriuretic peptide [8] and that some antidiabetic agents, such as glucagon-like peptide-1 receptor agonist and SGLT2 inhibitors, improved the clinical course of HF even without significant changes in levels of NPs amongst patients with T2DM [27,28,29,30]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.